logo
Share SHARE
FONT-SIZE Plus   Neg

BMY, Pfizer Records Consistent Results In Sub-analysis Of Eliquis Vs. Warfarin

Bristol-Myers Squibb Co. (BMY) and Pfizer Inc. (PFE) said the Phase III Aristotle trial of Eliquis in comparison with warfarin for the the prevention of stroke or systemic embolism in nonvalvular atrial fibrillation were consistent with the overall results of the Aristotle trial. Further, the companies said the Eliquis compared with warfarin reduced stroke or systemic embolism, caused fewer major bleeding events, and reduced all-cause mortality in NVAF patients with or without valvular heart disease or VHD.

The Aristotle trial excluded patients with clinically significant mitral stenosis, or a mechanical prosthetic heart valve.

The results of the sub analysis were presented in an oral session today at the ESC Congress 2013 in Amsterdam, The Netherlands.

The subanalysis evaluated Eliquis compared to warfarin in patients with or without other types of VHD, who were eligible for enrollment in the Aristotle

trial, including mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis, tricuspid regurgitation, or valve surgery. 4,808 patients participated in the sub analysis.

Eliquis is an oral inhibitor of blood clotting protein Factor Xa.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Bank of Nova Scotia or otherwise known as Scotiabank, Friday reported lower net profit for the third quarter, in the absence of a year-ago gain. Earnings per share, however, came in line with the Street view. Further, the company said it raised its quarterly dividend by 2 cents. Non-traditional discount and variety stores operator Big Lots Inc. (BIG) Friday reported a decline in net profit for the second quarter, while net sales grew 1.2 percent from the prior year. Comparable sales for the quarter increased 2.8 percent. Google has rejected the European Union's charges that it abused its market power and the demanded that it change the way it ranks online comparison shopping services in its search results, setting up a potentially long legal battle with the EU regulator empowered to levy billions of euros in fines
comments powered by Disqus
Follow RTT